Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M182,977Revenue $M49,995Net Margin (%)13.6Altman Z-Score2.3
Enterprise Value $M211,178EPS $2.8Operating Margin %17.3Piotroski F-Score4
P/E(ttm)27.3Beneish M-Score-2.7Pre-tax Margin (%)15.6Higher ROA y-yN
Price/Book2.510-y EBITDA Growth Rate %-0.7Quick Ratio0.6Cash flow > EarningsY
Price/Sales3.75-y EBITDA Growth Rate %-3.8Current Ratio0.8Lower Leverage y-yN
Price/Free Cash Flow22.4y-y EBITDA Growth Rate %-20.0ROA % (ttm)5.1Higher Current Ratio y-yN
Dividend Yield %3.6PEG--ROE % (ttm)8.9Less Shares Outstanding y-yY
Payout Ratio %97.0Shares Outstanding M2,381ROIC % (ttm)7.8Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 76.841%Add 1.59%6,287,099
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 76.84-13%Reduce -1.35%45,107,085
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 76.84-13%Reduce -2.74%242,201
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 76.84-13%Reduce -3.15%27,643
NVSJohn Rogers 2015-12-31 Buy 0.01%$83.96 - $95.03
($88.53)
$ 76.84-13%New holding11,267
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 76.84-13%Add 0.92%6,188,893
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 76.84-13%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 76.84-23%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 76.84-23%Add 1.28%6,132,211
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 76.84-23%Reduce -2.04%249,022
NVSKahn Brothers 2015-09-30 Add0.01%$89.52 - $106.12
($99.32)
$ 76.84-23%Add 1.42%28,543
NVSMario Gabelli 2015-09-30 Reduce$89.52 - $106.12
($99.32)
$ 76.84-23%Reduce -9.48%7,540
NVSDodge & Cox 2015-06-30 Reduce-0.19%$98.34 - $105.5
($102.32)
$ 76.84-25%Reduce -4.12%47,970,345
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 76.84-25%Reduce -9.12%28,143
NVSTweedy Browne 2015-06-30 Reduce-0.02%$98.34 - $105.5
($102.32)
$ 76.84-25%Reduce -2.31%254,217
NVSKen Fisher 2015-06-30 Add0.01%$98.34 - $105.5
($102.32)
$ 76.84-25%Add 1.08%6,054,640
NVSMario Gabelli 2015-06-30 Reduce$98.34 - $105.5
($102.32)
$ 76.84-25%Reduce -15.35%8,330
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 76.84-22%Reduce -0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 76.84-22%Reduce -2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.97)
$ 76.84-22%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15412.27view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Samuel Isaly Trades in Health Care Stocks in 1st Quarter Apr 27 2016 
    Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
    Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
    Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
    Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
    Valeant's Share Price Continues to Decline Feb 05 2016 
    10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
    Guru Stocks at 52-Week Lows Jan 26 2016 
    Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 
    Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows Jan 04 2016 

    More From Other Websites
    Radius Health (RDUS): Stock to Surprise in Q1 Earnings? May 02 2016
    2 Dirt-Cheap Big Pharma Stocks Poised to Beat Biotech's Bad Rap May 02 2016
    Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung... Apr 29 2016
    ETF’s with exposure to Novartis AG : April 28, 2016 Apr 28 2016
    Tysabri Reports Strong Patient Growth in 1Q16 Apr 28 2016
    Analysts’ Recommendations: Most Rate Novartis a ‘Buy’ Apr 27 2016
    [$$] Sir Andrew Witty fuels GSK turnround hopes with results boost Apr 27 2016
    Novartis AG :NVS-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 27 2016
    Drugs giant GSK reports slump in profits Apr 27 2016
    Glaxo Profit Rises for First Time Since 2013, Tops Estimates Apr 27 2016
    Novartis’s Pharmaceutical Revenue Reported Growth in 1Q16 Apr 27 2016
    Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of... Apr 27 2016
    Why Did Sandoz Report Operational Growth? Apr 26 2016
    Novartis Reported Operational Growth in Its 1Q16 Earnings Apr 25 2016
    Novartis’s 1Q16 Earnings Got a Neutral Response from Investors Apr 25 2016
    Novartis may dispose $13.8B in Roche stake Apr 25 2016
    April 25 Premarket Briefing: 10 Things You Should Know Apr 25 2016
    Novartis could refuel M&A machine with $14 billion Roche stake sale Apr 25 2016
    Novartis to prepare the sale of its Roche stake, paper says Apr 25 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)